{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:15:05Z","timestamp":1783379705032,"version":"3.54.6"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.vaccine.2026.128326","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:11:48Z","timestamp":1772806308000},"page":"128326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Annual immunogenicity measurements in randomized clinical trials help reveal heterogeneity in long-term vaccine efficacy: a pooled logistic regression modeling study"],"prefix":"10.1016","volume":"78","author":[{"given":"Julie","family":"Dud\u00e1\u0161ov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zden\u011bk","family":"Valenta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea","family":"M\u0103g\u0103lie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett T.","family":"Nieddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Sachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128326_bb0005","series-title":"Design and analysis of vaccine studies","first-page":"1","author":"Halloran","year":"2010"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128326_bb0010","first-page":"68","article-title":"Immunosenescence and challenges of vaccination against influenza in the aging population","volume":"3","author":"Reber","year":"2012","journal-title":"Aging Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128326_bb0015","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00084-18","article-title":"Factors that influence the immune response to vaccination","volume":"32","author":"Zimmermann","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2026.128326_bb0020","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jaci.2009.12.980","article-title":"Overview of the immune response","volume":"125","author":"Chaplin","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2026.128326_bb0025","first-page":"2060","article-title":"Observational studies and the difficult quest for causality: lessons from vaccine effectiveness and impact studies","volume":"45","author":"Lipsitch","year":"2016","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2026.128326_bb0030","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1016\/j.vaccine.2017.04.037","article-title":"Case-control vaccine effectiveness studies: preparation, design, and enrollment of cases and controls","volume":"35","author":"Verani","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128326_bb0035","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMoa2115481","article-title":"Duration of protection against mild and severe disease by Covid-19 vaccines","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128326_bb0040","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071249","article-title":"Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records","volume":"378","author":"Horne","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2026.128326_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.lana.2021.100154","article-title":"Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: a population-based study","volume":"6","author":"Cerqueira-Silva","year":"2022","journal-title":"Lancet Regional health \u2013 Americas"},{"key":"10.1016\/j.vaccine.2026.128326_bb0050","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41591-021-01392-9","article-title":"Evaluation of the extended efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection","volume":"27","author":"Salje","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.128326_bb0055","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1751-7915.2011.00277.x","article-title":"New developments and concepts related to biomarker application to vaccines","volume":"5","author":"Ahmed","year":"2012","journal-title":"J Microbial Biotechnol"},{"key":"10.1016\/j.vaccine.2026.128326_bb0060","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/14760584.2024.2331065","article-title":"The durability of vaccine-induced protection: an overview","volume":"23","author":"Vashishtha","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128326_bb0065","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/cis238","article-title":"Nomenclature for immune correlates of protection after vaccination","volume":"54","author":"Plotkin","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128326_bb0070","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00006454-200101000-00013","article-title":"Immunologic correlates of protection induced by vaccination","volume":"20","author":"Plotkin","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2026.128326_bb0075","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1086\/589862","article-title":"Correlates of vaccine-induced immunity","volume":"47","author":"Plotkin","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128326_bb0080","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1093\/infdis\/jiu568","article-title":"Increasing complexity of vaccine development","volume":"212","author":"Plotkin","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128326_bb0085","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1016\/j.vaccine.2019.10.046","article-title":"Updates on immunologic correlates of vaccine-induced protection","volume":"38","author":"Plotkin","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128326_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1081107","article-title":"Recent updates on correlates of vaccine-induced protection","volume":"13","author":"Plotkin","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128326_bb0095","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/imr.13091","article-title":"Correlates of protection against SARS-CoV-2 infection and COVID-19 disease","volume":"310","author":"Goldblatt","year":"2022","journal-title":"Immunol Rev"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128326_bb0100","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ni.2039","article-title":"Immunological mechanisms of vaccination","volume":"12","author":"Pulendran","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2026.128326_bb0105","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/sim.2282","article-title":"A model for immunological correlates of protection","volume":"25","author":"Dunning","year":"2006","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2026.128326_bb0110","doi-asserted-by":"crossref","first-page":"841","DOI":"10.4161\/hv.6.10.12636","article-title":"A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes","volume":"6","author":"Coudeville","year":"2010","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2026.128326_bb0115","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12874-019-0687-y","article-title":"Assessing correlates of protection in vaccine trials: statistical solutions in the context of high vaccine efficacy","volume":"19","author":"Callegaro","year":"2019","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.vaccine.2026.128326_bb0120","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/bimj.202100015","article-title":"Assurance in vaccine efficacy clinical trial design based on immunological responses","volume":"63","author":"Callegaro","year":"2021","journal-title":"Biom J"},{"key":"10.1016\/j.vaccine.2026.128326_bb0125","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-021-00377-6","article-title":"A method to estimate probability of disease and vaccine efficacy from clinical trial immunogenicity data","volume":"6","author":"Dudasova","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.128326_bb0130","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12874-024-02197-3","article-title":"Elucidating vaccine efficacy using a correlate of protection, demographics, and logistic regression","volume":"24","author":"Dudasova","year":"2024","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.vaccine.2026.128326_bb0135","author":"Dudasova"},{"key":"10.1016\/j.vaccine.2026.128326_bb0140","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12874-015-0096-9","article-title":"Some extensions in continuous models for immunological correlates of protection","volume":"15","author":"Dunning","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.vaccine.2026.128326_bb0145","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/INF.0b013e3182367662","article-title":"Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children","volume":"30","author":"Black","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2026.128326_bb0150","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-10-18","article-title":"Relationship between haemagglutinationinhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model","volume":"10","author":"Coudeville","year":"2010","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.vaccine.2026.128326_bb0155","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1016\/j.vaccine.2021.02.074","article-title":"Correlation of protection against varicella in a randomized phase III varicella-containing vaccine efficacy trial in healthy infants","volume":"39","author":"Habib","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128326_bb0160","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1080\/21645515.2015.1118595","article-title":"Validation and evaluation of serological correlates of protection for inactivated enterovirus 71 vaccine in children aged 6-35 months","volume":"12","author":"Jin","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2026.128326_bb0165","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1080\/14760584.2017.1335603","article-title":"Correlates of protection for inactivated enterovirus 71 vaccine: the analysis of immunological surrogate endpoints","volume":"16","author":"Zhu","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128326_bb0170","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41541-024-00937-6","article-title":"The effect of immune correlates on the precision of vaccine efficacy evaluation: time-to-event models and demographics","volume":"9","author":"Dudasova","year":"2024","journal-title":"NPJ Vaccines"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128326_bb0175","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.cmi.2018.01.018","article-title":"Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America","volume":"24","author":"Arredondo-Garc\u00eda","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2026.128326_bb0180","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076321","article-title":"Effectiveness of the live zoster vaccine during the 10 years following vaccination: real world cohort study using electronic health records","volume":"383","author":"Klein","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2026.128326_bb0185","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/cid\/ciu918","article-title":"Long-term persistence of zoster vaccine efficacy","volume":"60","author":"Morrison","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128326_bb0190","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/cid\/cis638","article-title":"Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy","volume":"55","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"19","key":"10.1016\/j.vaccine.2026.128326_bb0195","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1016\/j.vaccine.2020.03.029","article-title":"Assessment of the long-term efficacy of a dengue vaccine against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus","volume":"38","author":"Dayan","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128326_bb0200","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128326_bb0205","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1080\/21645515.2019.1658503","article-title":"A review of Dengvaxia\u00ae: development to deployment","volume":"15","author":"Thomas","year":"2019","journal-title":"Human Vacc Immunother"},{"key":"10.1016\/j.vaccine.2026.128326_bb0210","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128326_bb0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003230","article-title":"Dengue virus neutralizing antibody levels associated with protection from infection in Thai cluster studies","volume":"8","author":"Buddhari","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"13","key":"10.1016\/j.vaccine.2026.128326_bb0220","doi-asserted-by":"crossref","DOI":"10.1172\/JCI147066","article-title":"Dengue vaccine breakthrough infections reveal properties of neutralizing antibodies linked to protection","volume":"131","author":"Henein","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2026.128326_bb0225","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128326_bb0230","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4049\/jimmunol.99.2.285","article-title":"A plaque reduction test for dengue virus neutralizing antibodies","volume":"99","author":"Russell","year":"1967","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2026.128326_bb0235","doi-asserted-by":"crossref","first-page":"825","DOI":"10.4269\/ajtmh.2009.08-0625","article-title":"Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: how alterations in assay conditions impact performance","volume":"81","author":"Thomas","year":"2009","journal-title":"Am J Trop Med Hygiene"},{"key":"10.1016\/j.vaccine.2026.128326_bb0240","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/infdis\/jiu279","article-title":"Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve","volume":"210","author":"Gilbert","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128326_bb0245","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/528696","article-title":"Varicella-zoster virus\u2013specific immune responses in elderly recipients of a herpes zoster vaccine","volume":"197","author":"Levin","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128326_bb0250","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1086\/522428","article-title":"A framework for assessing immunological correlates of protection in vaccine trials","volume":"196","author":"Qin","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128326_bb0255","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1073\/pnas.1522136113","article-title":"Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort","volume":"113","author":"Katzelnick","year":"2016","journal-title":"PNAS"},{"key":"10.1016\/j.vaccine.2026.128326_bb0260","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.1038\/s41467-021-26117-x","article-title":"SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques","volume":"12","author":"Roozendaal","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128326_bb0265","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2307\/270718","article-title":"Discrete-time methods for the analysis of event histories","volume":"13","author":"Allison","year":"1982","journal-title":"Sociol Methodol"},{"key":"10.1016\/j.vaccine.2026.128326_bb0270","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/sim.4780091214","article-title":"Relation of pooled logistic regression to time dependent cox regression analysis: the Framingham heart study","volume":"9","author":"D\u2019Agostino","year":"1990","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2026.128326_bb0275","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12874-016-0248-6","article-title":"A comparison of time dependent cox regression, pooled logistic regression and cross sectional pooling with simulations and an application to the Framingham heart study","volume":"16","author":"Ngawa","year":"2016","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.vaccine.2026.128326_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104264","article-title":"Accelerating model-informed decisions for COVID-19 vaccine candidates using a model-based meta-analysis approach","volume":"84","author":"Kandala","year":"2022","journal-title":"eBioMedicine"},{"key":"10.1016\/j.vaccine.2026.128326_bb0285","doi-asserted-by":"crossref","first-page":"103651","DOI":"10.1016\/j.ebiom.2021.103651","article-title":"Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis","volume":"73","author":"Maas","year":"2021","journal-title":"eBioMedicine"},{"key":"10.1016\/j.vaccine.2026.128326_bb0290","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMe2028079","article-title":"The power of antibody-based surveillance","volume":"383","author":"Alter","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128326_bb0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v011.i10","article-title":"Econometric computing with HC and HAC covariance matrix estimators","volume":"11","author":"Zeileis","year":"2004","journal-title":"J Stat Softw"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128326_bb0390","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.2307\/2533444","article-title":"Robust variance estimation for the case-cohort design","volume":"50","author":"Barlow","year":"1994","journal-title":"Biometrics"},{"key":"10.1016\/j.vaccine.2026.128326_bb0300","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/biom.13377","article-title":"Improving precision and power in randomized trialsfor COVID-19 treatments using covariate adjustment, for binary, ordinal, and time-to-event outcomes","volume":"77","author":"Benkeser","year":"2021","journal-title":"Biometrics"},{"key":"10.1016\/j.vaccine.2026.128326_bb0305","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/sim.3503","article-title":"Response to Andrew Dunning\u2019s comment on \u2018evaluating a surrogate endpoint at three levels, with application to vaccine development\u2019","volume":"28","author":"Gilbert","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2026.128326_bb0310","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","article-title":"Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study","volume":"398","author":"Tartof","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128326_bb0315","series-title":"Guidance for Industry: Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products","author":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER)","year":"2023"},{"key":"10.1016\/j.vaccine.2026.128326_bb0320","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/bcp.13577","article-title":"Full covariate modelling approach in population pharmacokinetics: understanding the underlying hypothesis tests and implications of multiplicity","volume":"84","author":"Xu","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.vaccine.2026.128326_bb0325","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/sim.4780080407","article-title":"Surrogate endpoints in clinical trials: definition and operational criteria","volume":"8","author":"Prentice","year":"1989","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128326_bb0330","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/cid\/cix766","article-title":"Dependency of vaccine efficacy on Preexposure and age: a closer look at a tetravalent dengue vaccine","volume":"66","author":"Yang","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128326_bb0335","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128326_bb0340","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s43856-025-00807-9","article-title":"Efficacy of monoclonal antibodies and maternal vaccination for prophylaxis of respiratory syncytial virus disease","volume":"5","author":"Plock","year":"2025","journal-title":"Commun Med"},{"key":"10.1016\/j.vaccine.2026.128326_bb0345","doi-asserted-by":"crossref","first-page":"106606","DOI":"10.1016\/j.ijantimicag.2022.106606","article-title":"Mechanistic models of COVID-19: insights into disease progression, vaccines, and therapeutics","volume":"60","author":"Desikan","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.vaccine.2026.128326_bb0350","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.xphs.2023.10.043","article-title":"A quantitative clinical pharmacology-based framework for model-informed vaccine development","volume":"113","author":"Desikan","year":"2024","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2026.128326_bb0355","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s43588-022-00198-0","article-title":"Modeling how antibody responses may determine the efficacy of COVID-19 vaccines","volume":"2","author":"Padmanabhan","year":"2022","journal-title":"Nature Computational Science"},{"key":"10.1016\/j.vaccine.2026.128326_bb0360","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1016\/j.vaccine.2007.02.069","article-title":"Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine","volume":"25","author":"Fraser","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128326_bb0365","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1016\/j.immuni.2025.11.007","article-title":"Quantifying the waning of humoral immunity","volume":"58","author":"Saha","year":"2025","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128326_bb0370","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1541-0420.2005.00344.x","article-title":"Combining multiple comparisons and modeling techniques in dose-response studies","volume":"61","author":"Bretz","year":"2005","journal-title":"Biometrics"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128326_bb0375","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/sim.6052","article-title":"Model-based dose finding under model uncertainty using general parametric models","volume":"33","author":"Pinheiro","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2026.128326_bb0380","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1208\/s12248-025-01157-z","article-title":"Randomized-Exposure Mixture-Model Analysis (REMIX) allowing Type-1 Error Controlled Exposure\u2013Response Modelling","volume":"28","author":"Wojtyniak","year":"2026","journal-title":"AAPS J"},{"key":"10.1016\/j.vaccine.2026.128326_bb0385","author":"Magalie"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26001349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26001349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T22:32:13Z","timestamp":1783377133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26001349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":78,"alternative-id":["S0264410X26001349"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128326","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Annual immunogenicity measurements in randomized clinical trials help reveal heterogeneity in long-term vaccine efficacy: a pooled logistic regression modeling study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128326","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s) and Merck & Co., Inc., Rahway, NJ, USA and its affiliates. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128326"}}